global presence
Local support from a global company
Huvepharma® has a distribution network which covers more than 90 countries in 6 continents. Find your nearest Huvepharma® representative today.
Find your local contact
- Change country
Product | 10.07.2020
Huvepharma® has obtained a BSA (Brand Specific Approval) registration in Europe for Monimax®, a microgranulated product combining monensin and nicarbazin.
The Official Journal entry can be found here (page 79).
- Huvepharma® has launched a new anticoccidial in Europe: Monimax®
- Monimax® is a microgranulated product combining monensin and nicarbazin
- Monimax® is registered for use in turkeys, broilers and laying hens
Coccidiosis remains a major concern for the poultry industry. Efficient coccidiosis control is paramount to safeguarding good performance. Suboptimal control of coccidiosis will decrease performance and, at the same time, may drive an increased use of antimicrobials for the treatment of intestinal problems for which coccidiosis is a trigger (dysbacteriosis, necrotic enteritis).
Monimax® is now registered for use in chickens for fattening, turkeys for fattening and chickens reared for laying in Europe. The synergy between monensin and nicarbazin allows the use of monensin and nicarbazin at lower concentrations (Vereechen et al., 2020), making it suitable for use in all conditions, all year round.
Monimax® has proven efficacy against all Eimeria species in chickens and turkeys. This new combination of monensin and nicarbazin will result in a synergistic effect against the current field species of Eimeria and data supports an improvement in poultry performance. Monimax® is registered and safe for use in turkeys and chickens, which makes the product convenient for use in feed mills producing feed for different poultry species. In addition, Monimax® improves bird welfare as good coccidiosis control will also improve litter quality which has a direct effect on foot pad lesions, an important welfare indicator.
You might also find this interesting
Article | 28.09.2020
Introducing Monimax® - A New Anticoccidial
Article | 24.10.2020
Unique New Product Demonstrates Efficacy and Performance
Article | 01.10.2020
Huvepharma Launches New Coccidiosis Control Product Monimax® in Europe
Article | 04.09.2020
Registration Of A New Anticoccidial in Europe
about us
Huvepharma®
Huvepharma® is a fast-growing, global pharmaceutical company with a focus on developing, manufacturing and marketing human and animal health and nutrition products.
more about us
Change country
The Huvepharma® distribution network covers 90 countries in 6 continents. Please select a country from the list below to see the products and services available in that region.
To view all products and services, select Global from the dropdown menu or click .
Change language
Huvepharma has a remarkable distribution network which covers 90 countries in 6 continents. To offer you the best services, we ask you to select your country.
Europe
top
Your browser is out of date!
Update your browser to view this website correctly. Update my browser now